Eli Lilly and Company Faces Regulatory and Pricing Policy Challenges

Eli Lilly and Company (LLY), a leading pharmaceutical company, has experienced a decline in value due to regulatory and pricing policy challenges. The RiverPark Large Growth Fund's Q1 2026 investor letter highlighted that Eli Lilly and Company (NYSE:LLY) declined by 14% and this situation may have a long-term impact on the company's revenue growth. The company has a market capitalization of $1.08 trillion and has gained 53.39% over the past 52 weeks. However, the Trump administration's continued push to codify 'most favored nation' (MFN) drug pricing into law and the expiration of Novo Nordisk's semaglutide patent in India in March 2026 have contributed to broader investor concerns about pricing power. Nevertheless, the company's management had already anticipated these pricing headwinds, guiding that price would be a drag on GLP-1 revenue growth in the low-to-mid teens range. Additionally, the volume growth for Mounjaro and Zepbound is substantially outpacing these price declines, with demand continuing to exceed supply across global markets. RiverPark Large Growth Fund views Eli Lilly and Company as one of the highest-quality growth franchises in global healthcare, with its leadership in obesity, diabetes, and Alzheimer's disease, robust patent portfolio, and expanding global manufacturing capacity supporting a multi-year trajectory of strong revenue and free cash flow growth. Despite the current pricing challenges, the company's pipeline across oncology and neuroscience provides significant additional optionality, making the current dislocation an attractive opportunity to own one of the world's premier growth franchises.